Artivion | CRY - Sales Revenues

Stock Price
22.77
Daily Change
-0.16 -0.70%
Monthly
-38.02%
Yearly
-22.84%
Q2 Forecast
22.31

Artivion reported $115.99M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
Accuray USD 116.17M 14.63M Dec/2024
AngioDynamics USD 79.43M 3.72M Sep/2025
Artivion USD 115.99M 2.6M Dec/2025
AtriCure USD 141.2M 700K Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Becton, Dickinson and Co. USD 4.7B 600M Mar/2026
Boston Scientific USD 5.2B 90M Mar/2026
Edwards Lifesciences USD 1.65B 80M Mar/2026
Inogen USD 74.93M 504K Sep/2024
Integra LifeSciences USD 391.9M 43M Mar/2026
J&J USD 24.1B 500M Mar/2026
Mesa Laboratories USD 62.84M 5.01M Dec/2024
Orthofix International USD 219.91M 14.28M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
ResMed USD 1.4B 0 Mar/2026
Stryker USD 6B 1.2B Mar/2026
Surmodics USD 29.57M 355K Jun/2025
Tandem Diabetes Care USD 247.22M 43.18M Mar/2026
Teleflex USD 548.3M 20.68M Mar/2026
Terumo JPY 296.63B 21.66B Dec/2025
Trinity Biotech USD 14.31M 1.55M Sep/2025